Gold prices bounce off 3-week lows; demand likely longer term
HERCULES, Calif. - Bio-Rad Laboratories, Inc. (NYSE:BIO and BIO.B), a life sciences company with a market capitalization of $6.9 billion and a "GOOD" overall financial health rating according to InvestingPro, announced Monday the appointment of Rajat Mehta as Executive Vice President, Global Commercial Operations, effective August 4, 2025. Mehta will succeed Mike Crowley, who is retiring after 26 years with the company.
Mehta joins Bio-Rad from Labcorp, where he served as Senior Vice President overseeing commercial operations for the company’s West Division. Previously, he worked as Vice President and General Manager of Applied Technologies at Thermo Fisher Scientific, managing a global business unit. His earlier career included commercial roles at Dow Chemical.
"Rajat’s proven track record in delivering above-market growth, building high-achieving teams, and driving alignment across multiple business segments will be instrumental as we continue to advance our long-term strategy," said Jon DiVincenzo, Bio-Rad’s President and Chief Operating Officer, according to the company’s press release.
Norman Schwartz, Bio-Rad’s Chairman and CEO, acknowledged Crowley’s contributions since joining in 1998, particularly during his tenure as EVP of Global Commercial Operations since 2014.
Mehta holds an MBA from The Wharton School at the University of Pennsylvania and a BS in Electrical Engineering from Kurkshetra University in India.
Bio-Rad Laboratories develops, manufactures, and markets products for life science research and clinical diagnostics markets. The company operates globally with approximately 7,500 employees and reported $2.6 billion in revenues in 2024. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 5.99 and operates with moderate debt levels. The company is currently trading below its Fair Value, with analysts expecting net income growth this year. Bio-Rad will report its next earnings on July 31, 2025. For deeper insights into Bio-Rad’s financials and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Bio-Rad Laboratories has reported impressive financial results for the first quarter of 2025. The company exceeded analysts’ expectations with an earnings per share of $2.54, surpassing the projected $1.80. Additionally, Bio-Rad’s revenue reached $585.4 million, slightly above the anticipated $573.22 million. In terms of product development, Bio-Rad has expanded its digital PCR portfolio by launching four new Droplet Digital PCR platforms. These include the QX Continuum ddPCR system and three QX700 series platforms, acquired through the purchase of Stilla Technologies.
Furthermore, a report by Cantor Fitzgerald highlighted insights from a discussion with Bio-Rad’s CEO regarding challenges in the biotechnology sector. The CEO expressed concerns over the potential impact of lowering drug prices on the biotechnology ecosystem. The report also noted Bio-Rad’s opposition to the Most Favored Nation model, suggesting it could shift the biotechnology hub to China. These developments underscore Bio-Rad Laboratories’ strategic moves in innovation and its stance on industry challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.